Targeted EGFR/HER2 Therapy to Overcome the Blood-Brain Barrier


Defining Mechanisms of Resistance to KRASG12C Inhibitors


Mechanisms of Resistance to Endocrine Therapy and CDK4/6 Inhibitors in ER+ Breast Cancer


Meet the Editors Roundtable


Driving Precision Medicine through Clinical Computational Oncology


Emerging Technologies II


Organotypic Modeling of Cancer and Immune Cell Dynamics


Inferring and Making Sense Out of Cancer Cell Phylogenies


Targeted Protein Degradation- A New Approach for Challenging Targets


Short Talk: MLL-Menin Inhibition Reverses Pre-leukemic Progenitor Self-renewal in NPM1 Mutant AML